"False"
Hoppa direkt till innehållet
umu.se
För studenter
Bibliotek
För medarbetare
Logga in
Student
Alla studenter måste byta lösenord efter 7 maj.
Redigera
Redigera innehåll på umu.se
English site
Sök
Meny
X stäng menyn
Meny
Sök
Sök inom:
Sök inom:
Allt
Utbildning
Forskning
Personal
Studentwebb
Nyheter
Andra söktjänster
Hitta kurser och program
Sök kursplan
Sök välkomstbrev
Bibliotekets söktjänst
Sök i regelverket
Huvudmenyn dold.
Logga in
Student
Alla studenter måste byta lösenord efter 7 maj.
Redigera
Redigera innehåll på umu.se
English
Peter Hammarsten
Kontakt
E-post
peter.hammarsten@umu.se
Telefon
090-785 15 97
Verksam vid
Anknytning
Anknuten som läkare till
Institutionen för medicinsk biovetenskap
Enhet: Patologi
Plats
By 6M, vån 2, Sjukhusområdet
Umeå universitet, 901 85 Umeå
Publikationer
Publikationer
2019
Prostate cancer induces C/EBPβ expression in surrounding epithelial cells which relates to tumor aggressiveness and patient outcome
The Prostate
, John Wiley & Sons 2019, Vol. 79, (5) : 435-445
Adamo, Hanibal Hani; Hammarsten, Peter; Hägglöf, Christina; et al.
2019
Immunoreactivity for prostate specific antigen and Ki67 differentiates subgroups of prostate cancer related to outcome
Modern Pathology
, Vol. 32, (9) : 1310-1319
Hammarsten, Peter; Josefsson, Andreas; Thysell, Elin; et al.
2016
High Caveolin-1 Expression in Tumor Stroma Is Associated with a Favourable Outcome in Prostate Cancer Patients Managed by Watchful Waiting
PLOS ONE
, Vol. 11, (10)
Hammarsten, Peter; Scherdin, Tove Dahl; Hagglöf, Christina; et al.
2015
High Lysyl Oxidase (LOX) in the Non-Malignant Prostate Epithelium Predicts a Poor Outcome in Prostate Cancer Patient Managed by Watchful Waiting
PLOS ONE
, Public library science 2015, Vol. 10, (10)
Nilsson, Maria; Hägglöf, Christina; Hammarsten, Peter; et al.
2015
Morphological and morphometric characterization of direct transdifferentiation of support cells into hair cells in ototoxin-exposed neonatal utricular explants
Hearing Research
, Vol. 321 : 1-11
Werner, Mimmi; Van De Water, Thomas R.; Hammarsten, Peter; et al.
2014
Local and systemic protumorigenic effects of cancer-associated fibroblast-derived GDF15
Cancer Research
, American Association for Cancer Research 2014, Vol. 74, (13) : 3408-3417
Bruzzese, Francesca; Hägglöf, Christina; Leone, Alessandra; et al.
2014
ErbB2 Receptor Immunoreactivity in Prostate Cancer: Relationship to the Androgen Receptor, Disease Severity at Diagnosis and Disease Outcome
PLOS ONE
, Public Library Science 2014, Vol. 9, (9)
Hammarsten, Peter; Winther, Johanna; Rudolfsson, Stina H; et al.
2014
TMPRSS2-ERG Expression Predicts Prostate Cancer Survival and Associates with Stromal Biomarkers
PLOS ONE
, Vol. 9, (2) : e86824-
Hägglöf, Christina; Hammarsten, Peter; Strömvall, Kerstin; et al.
2014
Potential upstream regulators of cannabinoid receptor 1 signaling in prostate cancer: A Bayesian network analysis of data from a tissue microarray
The Prostate
, Vol. 74, (11) : 1107-1117
Häggström, Jenny; Cipriano, Mariateresa; Plym Forshell, Linus; et al.
2014
High density of S100A9 positive inflammatory cells in prostate cancer stroma is associated with poor outcome
European Journal of Cancer
, Vol. 50, (10) : 1829-1835
Tidehag, Viktor; Hammarsten, Peter; Egevad, Lars; et al.
2013
Association between cannabinoid CB1 receptor expression and Akt signalling in prostate cancer
PLOS ONE
, Vol. 8, (6) : e65798-
Cipriano, Mariateresa; Häggström, Jenny; Hammarsten, Peter; et al.
2013
Tumour epithelial expression levels of endocannabinoid markers modulate the value of endoglin-positive vascular density as a prognostic marker in prostate cancer
Biochimica et Biophysica Acta - Molecular and Cell Biology of Lipids
, Vol. 1831, (10) : 1579-1587
Fowler, Christopher J.; Josefsson, Andreas; Thors, Lina; et al.
2012
Phospho-Akt Immunoreactivity in Prostate Cancer: Relationship to Disease Severity and Outcome, Ki67 and Phosphorylated EGFR Expression
PLOS ONE
, Vol. 7, (10) : e47994-
Hammarsten, Peter; Cipriano, Mariateresa; Josefsson, Andreas; et al.
2011
Tumor indicating normal tissue could be a new source of diagnostic and prognostic markers for prostate cancer
Expert Opinion in Medical Diagnostics
, Informa Healthcare 2011, Vol. 5, (1) : 37-47
Halin Bergström, Sofia; Hammarsten, Peter; Adamo, Hani; et al.
2011
Prostate cancer increases hyaluronan in surrounding nonmalignant stroma, and this response is associated with tumor growth and an unfavorable outcome
American Journal of Pathology
, Vol. 179, (4) : 1961-1968
Josefsson, Andreas; Adamo, Hani; Hammarsten, Peter; et al.
2011
LRIG1 and the liar paradox in prostate cancer: A study of the expression and clinical significance of LRIG1 in prostate cancer.
International Journal of Cancer
, Wiley 2011, Vol. 128, (12) : 2843-2852
Thomasson, Marcus; Wang, Baofeng; Hammarsten, Peter; et al.
2010
Tumour cannabinoid CB(1) receptor and phosphorylated epidermal growth factor receptor expression are additive prognostic markers for prostate cancer
PLOS ONE
, Vol. 5, (12) : e15205-
Fowler, Christopher J; Hammarsten, Peter; Bergh, Anders
2010
Low levels of phosphorylated epidermal growth factor receptor in nonmalignant and malignant prostate tissue predict favorable outcome in prostate cancer patients.
Clinical Cancer Research
, Vol. 16, (4) : 1245-1255
Hammarsten, Peter; Karalija, Amar; Josefsson, Andreas; et al.
2010
Stromal PDGFRbeta expression in prostate tumors and non-malignant prostate tissue predicts prostate cancer survival
PLOS ONE
, Vol. 5, (5) : e10747-
Hägglöf, Christina; Hammarsten, Peter; Josefsson, Andreas; et al.
2010
Mast cells are novel independent prognostic markers in prostate cancer and represent a target for therapy
American Journal of Pathology
, Vol. 177, (2) : 1031-1041
Johansson, Anna; Rudolfsson, Stina; Hammarsten, Peter; et al.
2010
Fatty acid amide hydrolase in prostate cancer: association with disease severity and outcome, CB1 receptor expression and regulation by IL-4
PLOS ONE
, Public Library of Science 2010, Vol. 5, (8) : e12275-
Thors, Lina; Bergh, Anders; Persson, Emma; et al.
2009
A high cannabinoid CB(1) receptor immunoreactivity is associated with disease severity and outcome in prostate cancer
European Journal of Cancer
, Vol. 45, (1) : 174-182
Chung, Sui Chu; Hammarsten, Peter; Josefsson, Andreas; et al.
2007
Androgen-insensitive prostate cancer cells transiently respond to castration treatment when growing in an androgen-dependent prostate environment.
The Prostate
, Vol. 67, (4) : 370-7
Halin, Sofia; Hammarsten, Peter; Wikström, Pernilla; et al.
2007
Inhibition of the epidermal growth factor receptor enhances castration-induced prostate involution and reduces testosterone-stimulated prostate growth in adult rats.
Prostate
, Vol. 67, (6) : 573-581
Hammarsten, Peter; Rudolfsson, Stina; Henriksson, Roger; et al.
2006
Inhibitory effects of castration in an orthotopic model of androgen-independent prostate cancer can be mimicked and enhanced by angiogenesis inhibition.
Clinical Cancer Research
, Vol. 12, (24) : 7431-7436
Hammarsten, Peter; Halin, Sofia; Wikström, Pernilla; et al.
2004
Neutralizing VEGF bioactivity with a soluble chimeric VEGF-receptor protein flt(1-3)IgG inhibits testosterone-stimulated prostate growth in castrated mice.
Prostate
, Vol. 58, (1) : 57-65
Lissbrant, Ingela Franck; Hammarsten, Peter; Lissbrant, Erik; et al.
Prostate cancer induces C/EBPβ expression in surrounding epithelial cells which relates to tumor aggressiveness and patient outcome
Adamo, Hanibal; Hammarsten, Peter; Hägglöf, Christina; et al.
Visa publikationer i DiVA
+ Visa mer
- Visa mindre